Levetiracetam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Levetiracetam: From Partial-Onset Seizures to Status Epilepticus
One-Sentence Summary
Levetiracetam is an established antiepileptic medication, widely used for partial-onset and generalized seizures. The TxGNN model predicts it may be effective for Status Epilepticus, and this is already the strongest-supported prediction in this evidence pack — backed by 26 clinical trials (including a landmark multicentre Phase 3 RCT) and 20 publications, several of which are randomized controlled trials and network meta-analyses.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy — partial-onset seizures (adjunctive and monotherapy) |
| Predicted New Indication | Status Epilepticus |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L1 |
| South Africa Market Status | Not currently marketed in South Africa |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note: Of the 10 TxGNN-predicted indications supplied in this evidence pack (visual epilepsy, eating seizures, orgasm-induced seizures, thinking seizures, startle epilepsy, audiogenic seizures, micturition-induced seizures, reading seizures, status epilepticus, beta-ketothiolase deficiency), status epilepticus is the only candidate reaching evidence level L1 with a “Proceed with Guardrails” recommendation. The other candidates — mostly rare reflex-epilepsy subtypes — remain at evidence level L3–L5 (“Research Question” or “Hold”) due to sparse or indirect evidence, and are not the focus of this report.
Why is This Prediction Reasonable?
Formal mechanism-of-action documentation for levetiracetam was not available in the source data for this evaluation (DrugBank MOA field returned a data gap). However, based on well-characterized pharmacology summarized in the supporting literature, levetiracetam binds to the synaptic vesicle protein SV2A, modulating vesicular neurotransmitter release and reducing abnormal, synchronized neuronal discharge. This is the same broad-spectrum antiepileptic mechanism that underlies its approved use in partial-onset and generalized seizures.
Status epilepticus is a neurological emergency defined by prolonged or repetitive seizure activity failing normal termination mechanisms — mechanistically, an extension of the same abnormal cortical hyperexcitability and synchronization that levetiracetam already targets in chronic epilepsy. Because levetiracetam is available in an intravenous formulation with rapid onset, favorable renal (non-hepatic) clearance, and minimal drug-drug interactions, it is pharmacologically well suited for acute seizure termination in emergency and intensive care settings.
Importantly, this is not a novel mechanistic extrapolation: intravenous levetiracetam is already used internationally as a second-line/alternative first-line agent for benzodiazepine-refractory status epilepticus, most notably validated in the ESETT trial (NCT01960075, published in Lancet and NEJM). The TxGNN prediction therefore reflects and reinforces existing real-world clinical practice rather than proposing an untested mechanistic hypothesis.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01960075 | Phase 3 | Completed | 478 | ESETT trial — multicentre RCT comparing fosphenytoin, valproic acid, and levetiracetam for benzodiazepine-refractory status epilepticus |
| NCT02920060 | Phase 2 | Completed | 80 | Open randomized study, levetiracetam vs sodium valproate in children with refractory generalized convulsive status epilepticus |
| NCT01150331 | Phase 3 | Completed | 203 | IV levetiracetam + clonazepam vs clonazepam alone in prehospital treatment of generalized tonic-clonic status epilepticus |
| NCT02056236 | N/A | Completed | 172 | TELSTAR trial — treatment of EEG-diagnosed status epilepticus after cardiopulmonary resuscitation |
| NCT07052136 | N/A | Completed | 138 | Levetiracetam vs valproic acid in pediatric status epilepticus |
| NCT04926844 | Phase 2 | Completed | 144 | Combined levetiracetam + midazolam vs midazolam alone in pediatric generalized convulsive status epilepticus |
| NCT07163572 | N/A | Completed | 152 | IV brivaracetam vs levetiracetam in pediatric status epilepticus |
| NCT06067412 | N/A | Completed | 70 | Phenytoin vs levetiracetam in pediatric status epilepticus |
| NCT06907173 | Phase 3 | Recruiting | 770 | KESETT trial — ketamine + levetiracetam vs levetiracetam alone for established status epilepticus |
| NCT07046611 | Phase 2/3 | Recruiting | 124 | Ketamine + levetiracetam as second-line therapy for pediatric benzodiazepine-refractory status epilepticus |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31774955 | 2019 | RCT | New England Journal of Medicine | ESETT — randomized trial of three anticonvulsants (levetiracetam, fosphenytoin, valproate) for benzodiazepine-refractory status epilepticus |
| 32203691 | 2020 | RCT (age-group analysis) | The Lancet | Efficacy of levetiracetam, fosphenytoin, and valproate by age group in established status epilepticus (ESETT extended analysis) |
| 36209676 | 2022 | Network Meta-analysis | Seizure | Comparative effectiveness ranking of treatments for benzodiazepine-resistant status epilepticus |
| 33060105 | 2021 | Systematic Review/Meta-analysis | Archives of Disease in Childhood | Levetiracetam for convulsive status epilepticus in childhood |
| 31830677 | 2020 | Meta-analysis | Seizure | Efficacy and safety of intravenous levetiracetam in status epilepticus |
| 35538830 | 2023 | Meta-analysis | CNS & Neurological Disorders Drug Targets | Comparison of levetiracetam and phenytoin in pediatric status epilepticus |
| 40119876 | 2025 | Cohort | Epilepsia | Comparison of lacosamide, levetiracetam, and valproate as second-line therapy in a large adult status epilepticus cohort |
| 38580318 | 2024 | Review | Seminars in Neurology | Update on pharmacological management of status epilepticus |
| 35976303 | 2022 | Review | Arquivos de Neuro-Psiquiatria | Diagnosis, monitoring and treatment of status epilepticus |
| 38117319 | 2024 | Review | Intensive Care Medicine | Status epilepticus management in the ICU |
South Africa Market Information
Levetiracetam has no active SAHPRA registrations recorded in the evidence pack (total_licenses: 0, market_status: "未上市" / not marketed). No product name, dosage form, or approved indication text is available for South Africa at this time. This is a key gap for repurposing feasibility: any move toward status-epilepticus use in South Africa would first require a marketed, SAHPRA-registered levetiracetam product (or an import/named-patient access pathway) before formulary or clinical-guideline adoption can proceed.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(No key warnings, contraindications, or drug-interaction data were available in the source evidence pack for this evaluation — all fields returned a data gap.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Status epilepticus is supported by evidence level L1 — a landmark completed Phase 3 RCT (ESETT), multiple additional completed RCTs across adult and pediatric populations, and several published meta-analyses/network meta-analyses — making it by far the strongest candidate in this evidence pack. IV levetiracetam is already used internationally as an established second-line/alternative first-line agent for status epilepticus, so this represents formalizing existing practice rather than a speculative new use. The main constraint is regulatory: levetiracetam is not currently registered or marketed in South Africa.
To proceed, the following is needed:
- SAHPRA registration or import pathway for an IV levetiracetam product in South Africa
- Full Professional Information (PI) — warnings, contraindications, and drug-interaction data (currently a data gap)
- Formal DrugBank/manufacturer mechanism-of-action documentation to support a clinical guideline submission
- Local (South African) clinical guideline or emergency medicine society input on positioning levetiracetam relative to existing status epilepticus protocols (benzodiazepines, phenytoin/fosphenytoin, valproate)
- Confirmation of IV formulation supply chain and cold-chain/storage requirements for emergency department and ICU use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.